0002064764 2026-01-01 2026-06-30 0002064764 2025-12-31 0002064764 2026-06-30 0002064764 2025-01-01 2025-06-30 0002064764 ifrs-full:OrdinarySharesMember 2024-12-31 0002064764 ifrs-full:SharePremiumMember 2024-12-31 0002064764 ifrs-full:CapitalReserveMember 2024-12-31 0002064764 ifrs-full:RetainedEarningsMember 2024-12-31 0002064764 2024-12-31 0002064764 ifrs-full:OrdinarySharesMember 2025-12-31 0002064764 ifrs-full:SharePremiumMember 2025-12-31 0002064764 ifrs-full:CapitalReserveMember 2025-12-31 0002064764 ifrs-full:RetainedEarningsMember 2025-12-31 0002064764 ifrs-full:OrdinarySharesMember 2025-01-01 2025-06-30 0002064764 ifrs-full:SharePremiumMember 2025-01-01 2025-06-30 0002064764 ifrs-full:CapitalReserveMember 2025-01-01 2025-06-30 0002064764 ifrs-full:RetainedEarningsMember 2025-01-01 2025-06-30 0002064764 ifrs-full:OrdinarySharesMember 2026-01-01 2026-06-30 0002064764 ifrs-full:SharePremiumMember 2026-01-01 2026-06-30 0002064764 ifrs-full:CapitalReserveMember 2026-01-01 2026-06-30 0002064764 ifrs-full:RetainedEarningsMember 2026-01-01 2026-06-30 0002064764 ifrs-full:OrdinarySharesMember 2025-06-30 0002064764 ifrs-full:SharePremiumMember 2025-06-30 0002064764 ifrs-full:CapitalReserveMember 2025-06-30 0002064764 ifrs-full:RetainedEarningsMember 2025-06-30 0002064764 2025-06-30 0002064764 ifrs-full:OrdinarySharesMember 2026-06-30 0002064764 ifrs-full:SharePremiumMember 2026-06-30 0002064764 ifrs-full:CapitalReserveMember 2026-06-30 0002064764 ifrs-full:RetainedEarningsMember 2026-06-30 0002064764 PLSM:PrefundedWarrantsMember PLSM:SecuritiesPurchaseAgreementMember 2026-06-26 0002064764 ifrs-full:WarrantsMember PLSM:SecuritiesPurchaseAgreementMember 2026-06-26 0002064764 PLSM:SecuritiesPurchaseAgreementMember 2026-06-26 2026-06-26 0002064764 ifrs-full:WarrantsMember PLSM:SecuritiesPurchaseAgreementMember 2026-06-26 2026-06-26 0002064764 PLSM:PrefundedWarrantsMember PLSM:SecuritiesPurchaseAgreementMember 2026-06-26 2026-06-26 0002064764 PLSM:SecuritiesPurchaseAgreementMember 2026-06-26 0002064764 PLSM:SecuritiesPurchaseAgreementMember 2026-06-26 2026-06-30 0002064764 ifrs-full:WarrantsMember 2026-06-26 0002064764 ifrs-full:WarrantsMember 2026-06-26 2026-06-26 0002064764 ifrs-full:Level2OfFairValueHierarchyMember PLSM:PrefundedWarrantsMember 2026-06-30 0002064764 ifrs-full:Level3OfFairValueHierarchyMember PLSM:PrefundedWarrantsMember 2026-06-30 0002064764 PLSM:PrefundedWarrantsMember 2026-06-30 0002064764 ifrs-full:Level2OfFairValueHierarchyMember ifrs-full:WarrantsMember 2026-06-30 0002064764 ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:WarrantsMember 2026-06-30 0002064764 ifrs-full:WarrantsMember 2026-06-30 0002064764 ifrs-full:Level2OfFairValueHierarchyMember 2026-06-30 0002064764 ifrs-full:Level3OfFairValueHierarchyMember 2026-06-30 0002064764 PLSM:NonadjustingEventMember 2026-01-21 2026-01-21 0002064764 PLSM:NonadjustingEventMember 2026-01-21 0002064764 PLSM:IsraelInnovationAuthorityMember PLSM:NonadjustingEventMember PLSM:HealthcareAIRegulatorySandboxProgramMember 2026-07-02 0002064764 PLSM:IsraelInnovationAuthorityMember PLSM:NonadjustingEventMember PLSM:HealthcareAIRegulatorySandboxProgramMember 2026-07-02 2026-07-02 0002064764 PLSM:IsraelInnovationAuthorityMember PLSM:NonadjustingEventMember PLSM:SmartScanAIProgramMember 2026-08-12 2026-08-12 iso4217:USD shares iso4217:USD shares pure iso4217:ILS iso4217:ILS shares 6-K PULSENMORE LTD. false 2026-06-30 PULSENMORE LTD. 6-K --12-31 0002064764

21604000

43584000

14635000

47531000

26180000

8791000

140000

4144000

2382000

800000

1391000

1832000

615000

6593000

6345000

2131000

81403000

80323000

26972000

13337000

13742000

4615000

1285000

752000

253000

5822000

5089000

1709000

20444000

19583000

6577000

101847000

99906000

33549000

1980000

3463000

1163000

33198000

11148000

4407000

4121000

1384000

938000

81000

27000

276000 278000 93000 1705000 1693000 569000

1023000

840000

282000

10329000

43674000

14666000

7886000 7575000 2544000

542000

319000

107000

8428000

7894000

2651000

18757000

51568000

17317000

2000

1000

256137000

86009000

10092000

10412000

3497000

-183141000

-218213000

-73275000

83090000

48338000

16232000

101847000

99906000

33549000

3999000

6080000

2042000

2542000

3855000

1294000

1457000

2225000

748000

8029000

8459000

2840000

5966000

6382000

2143000

8083000

8141000

2734000

20621000

20757000

6969000

4766000

15962000

5359000

2231000

1647000

553000

-2535000

-14315000

-4806000

-23156000

-35072000

-11775000

1000

-23157000

-35072000

-11775000

3.6

5.39

1.83

6429059

6502844

1562500

2000

253205000

10968000

-167288000

96887000

-23157000

506000

471000

-199000

272000

280000 -280000

2000

253956000

10995000

-190445000

74508000

2000

256137000

10092000

-183141000

83090000

-35072000

320000

2000

256137000

10412000

-218213000

48338000

1000

86009000

3390000

-61500000

27900000

-11775000

107000

1000

86009000

3497000

-73275000

16232000

-15570000

-17571000

-5900000

97000

134000

45000

-2289000

19231000

6458000

964000

1291000

434000

-1422000

20388000

6847000

22507000

7558000

1738000

584000

4000

287000 160000 53000

1319000

574000

652000

218000

94000 59000 20000

368000

19898000

6683000

-16624000

22715000

7630000

41170000

21604000

7255000

-105000

-735000

-250000

24441000

43584000

14635000

-23157000

-35072000

-11775000

1432000

1521000

511000

506000

320000

107000

15000

-12527000

-4207000

-3356000

-1627000

-546000

5279000

15995000

5371000

1240000

1762000

592000

-22000

-441000

-149000

1465000

-157000

-53000

-207000

1483000

498000

-379000

-286000

-97000

193000

-857000

-288000

18000

2000

1000

2308000 1506000 504000

-15570000

-17571000

-5900000

110000 37000 -268000 NOTE 1 – GENERAL INFORMATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">A)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">General</td></tr> </table> Pulsenmore Ltd. (separately and collectively referred to with its wholly-owned subsidiaries as the “Company” or “Pulsenmore”) is an Israeli-based company, incorporated in Israel, and commenced its operations on October 27, 2014. The Company’s registered office is located at 8 Omarim Street, Omer, Israel. In March 2022, the Company established a wholly owned subsidiary, Pulsenmore Americas LLC (hereinafter – the “U.S. Subsidiary”), located in Boston, USA. The U.S. Subsidiary was incorporated under Delaware state law and began operations on March 10, 2022. In February 2023, the Company established a wholly owned subsidiary, Pulsenmore Korea (hereinafter – the “Korean Subsidiary”), located in Seongnam, South Korea. On December 31 2025, the Korean Subsidiary commenced a process of gradual shutdown over a period of five years which will lead to dissolution at the end of that period. As of June 30, 2026, the Company operates in a one operating segment, focusing on the research, development, manufacturing, and global marketing of innovative technological solutions, specifically portable ultrasound devices for home use. These devices enable remote physical examinations and monitoring via telemedicine technology. The Company develops and sells miniaturized ultrasound systems. The Company’s shares are traded on Tel-Aviv Stock Exchange (TASE) since 2021. In addition, On January 21, 2026, the Company completed registration on the Nasdaq and became a dual-listed company. On August 26, 2025, the Company received from a European certification body an EU Quality Management System Certificate for Regulation (CE MDR), valid until August 19, 2030. On October 31, 2025, the Company received approval to market the Company’s home ultrasound product from the U.S. Food and Drug Administration (FDA). <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">B)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">War in Israel</td></tr> </table> In October 2023, Israel was attacked by Hamas, a terrorist organization and entered a state of war. Since the commencement of these events, there have been additional active hostilities, including with Hezbollah in Lebanon, the Houthi movement which controls parts of Yemen, and with Iran. In response to ongoing Iranian aggression and support of proxy attacks against Israel, on June 12, 2025, Israel conducted a series of preemptive defensive air strikes in Iran targeting Iran’s nuclear program and military commanders. On June 24, 2025, a ceasefire with Iran was reached. On October 9, 2025, Israel, Hamas, the United States and other countries in the region agreed to a framework for a ceasefire in Gaza between Israel and Hamas. While that ceasefire has been mostly maintained, in late February 2026, Israel and the United States preemptively attacked Iran. As part of this conflict, Iran and Hezbollah have launched missile attacks throughout Israel. As a result, the Israeli government imposed restrictions on opening of non-essential places of business and announced recruitment of military reserves. The Company considered the impact of the war and determined that there were no material adverse impacts on the consolidated financial statements, including related significant estimates made by management, for the period ended June 30, 2026. NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS NOTE 1 – GENERAL INFORMATION (cont.) However, at this time, it is not possible to predict the intensity or duration of the war, nor can the Company predict how this war will ultimately affect Israel’s economy in general. The Company continues to monitor the situation closely and examine the potential disruptions that could adversely affect its operations. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">D)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Approval of condensed consolidated financial statements</td></tr> </table> These condensed consolidated financial statements were authorized for issuance by the board of directors on August 27, 2026, and should be read in conjunction with the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025 (the “2025 Annual Report”) filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2026.

NOTE 2 – BASIS OF PREPARATION OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">A)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Basis of presentation of the financial statements</td></tr> </table> The Company’s condensed consolidated financial statements for the six months ended June 30, 2026, have been prepared in accordance with International Accounting Standard (“IAS”) 34, “Interim Financial Reporting”. These condensed consolidated financial statements, which are unaudited, do not include all of the information and disclosures that would otherwise be required in a complete set of annual financial statements and should be read in conjunction with the annual financial statements for the year ended December 31, 2025, and their accompanying notes, which have been prepared in accordance with IFRS Accounting Standards as published by the International Accounting Standards Board. The results of operations for the six months ended June 30, 2026, are not necessarily indicative of the results that may be expected for the entire fiscal year ending December 31, 2026, or for any other interim period. <p id="xdx_848_eifrs-full--DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_zKnSaFdpZKG2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify; text-indent: 0pt"> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">B)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Convenience translation into U.S. dollars</td></tr> </table> The reported NIS amounts as of June 30, 2026 and for the six-month period then ended have been translated into U.S. dollars (“US dollars”, “USD”, “$”). All figures were translated using the representative exchange rate as of June 30, 2026 ($1 = NIS 2.978). The translation was made solely for the convenience of the reader. The dollar amount presented in these financial statements should not be construed to represent amounts receivable or payable in dollars or convertible into dollars, unless otherwise indicated in these financial statements. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top"><td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.25in">C)</td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">Estimates and judgments </td></tr> </table> The preparation of the Condensed Interim Financial Information requires management to exercise judgment and use significant accounting estimates and assumptions. These affect the application of the Company’s accounting policies and the reported amounts of assets, liabilities, income, and expenses. Actual results may differ materially from these estimates. In preparing these Condensed Interim Financial Information, the significant accounting judgments and the uncertainties associated with key sources of estimates are consistent with those in the consolidated annual financial statements for the year ended December 31, 2025.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">A)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Basis of presentation of the financial statements</td></tr> </table> The Company’s condensed consolidated financial statements for the six months ended June 30, 2026, have been prepared in accordance with International Accounting Standard (“IAS”) 34, “Interim Financial Reporting”. These condensed consolidated financial statements, which are unaudited, do not include all of the information and disclosures that would otherwise be required in a complete set of annual financial statements and should be read in conjunction with the annual financial statements for the year ended December 31, 2025, and their accompanying notes, which have been prepared in accordance with IFRS Accounting Standards as published by the International Accounting Standards Board. The results of operations for the six months ended June 30, 2026, are not necessarily indicative of the results that may be expected for the entire fiscal year ending December 31, 2026, or for any other interim period.

<p id="xdx_848_eifrs-full--DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_zKnSaFdpZKG2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify; text-indent: 0pt"> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">B)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Convenience translation into U.S. dollars</td></tr> </table> The reported NIS amounts as of June 30, 2026 and for the six-month period then ended have been translated into U.S. dollars (“US dollars”, “USD”, “$”). All figures were translated using the representative exchange rate as of June 30, 2026 ($1 = NIS 2.978). The translation was made solely for the convenience of the reader. The dollar amount presented in these financial statements should not be construed to represent amounts receivable or payable in dollars or convertible into dollars, unless otherwise indicated in these financial statements.

2.978

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top"><td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.25in">C)</td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">Estimates and judgments </td></tr> </table> The preparation of the Condensed Interim Financial Information requires management to exercise judgment and use significant accounting estimates and assumptions. These affect the application of the Company’s accounting policies and the reported amounts of assets, liabilities, income, and expenses. Actual results may differ materially from these estimates. In preparing these Condensed Interim Financial Information, the significant accounting judgments and the uncertainties associated with key sources of estimates are consistent with those in the consolidated annual financial statements for the year ended December 31, 2025.

<p id="xdx_802_eifrs-full--DisclosureOfMaterialAccountingPolicyInformationExplanatory_zoqdQZKczNYc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0pt">NOTE 3 – SIGNIFICANT ACCOUNTING POLICIES Significant accounting policies and calculation methods that have been applied in the preparation of the Condensed Interim Financial Information are consistent with those used in the preparation of the Company’s 2025 annual Consolidated Financial Statements. As to accounting policy relating to new issued warrants and pre-funded warrants classified as financial liabilities (see note 4).

NOTE 4 – FINANCINGS June 2026 private placement On June 26, 2026, the Company entered into a Securities Purchase Agreement with a healthcare-focused institutional investor, for the purchase and sale of pre-funded warrants to purchase <span id="xdx_900_eifrs-full--NumberOfSharesIssued_iI_c20260626__ifrs-full--TypesOfContractsAxis__custom--SecuritiesPurchaseAgreementMember__ifrs-full--ComponentsOfEquityAxis__custom--PrefundedWarrantsMember_zhE0MeXUxHBl" title="Number of shares issued">1,562,500 ordinary shares and ordinary warrants to purchase up to <span id="xdx_90E_eifrs-full--NumberOfSharesIssued_iI_c20260626__ifrs-full--TypesOfContractsAxis__custom--SecuritiesPurchaseAgreementMember__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantsMember_zbP1eHxRsBs8" title="Number of shares issued">1,562,500 ordinary shares in a private placement at a combined purchase price of $<span id="xdx_903_eifrs-full--ParValuePerShare_iI_uUSDPShares_c20260626__ifrs-full--TypesOfContractsAxis__custom--SecuritiesPurchaseAgreementMember__ifrs-full--ComponentsOfEquityAxis__custom--PrefundedWarrantsMember_zZEArSclkqRj" title="Purchase price"><span id="xdx_901_eifrs-full--ParValuePerShare_iI_uUSDPShares_c20260626__ifrs-full--TypesOfContractsAxis__custom--SecuritiesPurchaseAgreementMember__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantsMember_zKl8FRj0WFD9" title="Purchase price">4.7999 per pre-funded warrant and accompanying warrant, representing a premium to the Nasdaq Minimum Price under Nasdaq rules. The gross proceeds from the offering were NIS <span id="xdx_90C_eifrs-full--ProceedsFromIssuingShares_pn5n6_uNIS_c20260626__20260626__ifrs-full--TypesOfContractsAxis__custom--SecuritiesPurchaseAgreementMember_z0vLib863gYi" title="Gross proceeds from offering">22.5 million (approximately $<span id="xdx_900_eifrs-full--ProceedsFromIssuingShares_pn5n6_uUSD_c20260626__20260626__ifrs-full--TypesOfContractsAxis__custom--SecuritiesPurchaseAgreementMember_zQTWPITxXd31" title="Gross proceeds from offering">7.5 million), before deducting placement agent commissions and other offering expenses in total amount of NIS <span id="xdx_902_eifrs-full--ShareIssueRelatedCost_pn5n6_uNIS_c20260626__20260626__ifrs-full--TypesOfContractsAxis__custom--SecuritiesPurchaseAgreementMember_zZHXP3wpEDfa" title="Proceeds from issuing other equity instruments">2.1 million (approximately $<span id="xdx_900_eifrs-full--ShareIssueRelatedCost_pn5n6_uUSD_c20260626__20260626__ifrs-full--TypesOfContractsAxis__custom--SecuritiesPurchaseAgreementMember_zyiiW4ebMXr" title="Commissions and other offering expenses">0.7 million). The ordinary warrants have an exercise price of $<span id="xdx_901_eifrs-full--WeightedAverageSharePrice2019_uUSDPShares_c20260626__20260626__ifrs-full--TypesOfContractsAxis__custom--SecuritiesPurchaseAgreementMember__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantsMember_zNDvlCDIJG2d" title="Exercise price">4.80 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance. The pre-funded warrants will have at an exercise price of $<span id="xdx_900_eifrs-full--WeightedAverageSharePrice2019_uUSDPShares_c20260626__20260626__ifrs-full--TypesOfContractsAxis__custom--SecuritiesPurchaseAgreementMember__ifrs-full--ComponentsOfEquityAxis__custom--PrefundedWarrantsMember_zAQY1hUTgzmg" title="Exercise price">0.0001 per share and are exercisable immediately until exercised in full. The pre-funded warrants and warrants were classified as liabilities on the consolidated statements of financial position. They were initially recorded at fair value and subsequently remeasured at each reporting period at fair value through profit or loss. The fair value of the pre-funded warrant liability is based on a valuation technique which is equal to the market price of the underlying share less the $0.0001 strike price. The pre-funded warrant’s fair value is evidenced based on a valuation technique using data from observable markets, therefore the difference between the fair value and the transaction price is recognized immediately as a day one loss. As of the transaction date, the excess of the initial fair value of pre-funded warrants over the transaction proceeds amounting to approximately NIS <span id="xdx_90A_eifrs-full--FinanceCosts_pn6n6_uNIS_c20260626__20260626__ifrs-full--TypesOfContractsAxis__custom--SecuritiesPurchaseAgreementMember__ifrs-full--ComponentsOfEquityAxis__custom--PrefundedWarrantsMember_zpPFOyOtfl62" title="Financial expenses">12 million (approximately $<span id="xdx_907_eifrs-full--FinanceCosts_pn6n6_uUSD_c20260626__20260626__ifrs-full--TypesOfContractsAxis__custom--SecuritiesPurchaseAgreementMember__ifrs-full--ComponentsOfEquityAxis__custom--PrefundedWarrantsMember_zby92IdFrFp8" title="Financial expenses">4 million) was recorded as financial expenses. The warrant liability estimates the fair value using a Black Scholes option pricing model calculation using the following inputs: stock price (Level 1 input); risk-free rates (Level 1 input); volatility (Level 3 input). The excess of initial fair value over the transaction proceeds of the warrant liability (hereinafter – “Deferred day 1 loss”) amounting to NIS 7.3 million (approximately $2.4 million) was deferred and will be released to financial expenses over the contractual life of the warrants (<span id="xdx_90B_ecustom--WeightedAverageRemainingContractualLifeOfOutstandingWarrants_dtY_c20260626__20260626__ifrs-full--TypesOfContractsAxis__custom--SecuritiesPurchaseAgreementMember_zgpAzsd30g0b" title="Warrants contractual life">5 years). From the date of the transaction until June 30, 2026, the Company released NIS <span id="xdx_906_eifrs-full--OtherExpenseByNature_pn3n3_uNIS_c20260626__20260630__ifrs-full--TypesOfContractsAxis__custom--SecuritiesPurchaseAgreementMember_zZSU9mIftrYg" title="Amount released to financial expenses">16 thousand (approximately $<span id="xdx_90B_eifrs-full--OtherExpenseByNature_pp2n3_uUSD_c20260626__20260630__ifrs-full--TypesOfContractsAxis__custom--SecuritiesPurchaseAgreementMember_zi1QnX6uOf0a" title="Amount released to financial expenses">5.3 thousand) to financial expenses. Since all the instruments that were issued are classified as liabilities, all transaction costs, in amount of NIS 2.1 million (approximately $<span id="xdx_900_eifrs-full--ShareIssueRelatedCost_pn5n6_uUSD_c20260626__20260626__ifrs-full--TypesOfContractsAxis__custom--SecuritiesPurchaseAgreementMember_z0PpjhgngmMe" title="Commissions and other offering expenses">0.7 million), were expensed, of which NIS <span id="xdx_901_ecustom--ShareIssueRelatedCostUnpaid_pn5n6_uNIS_c20260626__20260626__ifrs-full--TypesOfContractsAxis__custom--SecuritiesPurchaseAgreementMember_z78HuxWL19Rl" title="Transaction costs not paid">0.3 million (approximately $<span id="xdx_900_ecustom--ShareIssueRelatedCostUnpaid_pn5n6_uUSD_c20260626__20260626__ifrs-full--TypesOfContractsAxis__custom--SecuritiesPurchaseAgreementMember_z19gQW6p3UNh" title="Transaction costs not paid">0.1 million) has not been paid yet. NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

1562500

4.7999

22500000

7500000

2100000

700000

4.80

0.0001

12000000

4000000

7300000 2400000 P5Y

16000

5300

2100000

700000

300000 100000

NOTE 5 – FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">A)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Financial instruments</td></tr> </table> The financial instruments of the Company, as of June 30, 2026, are accounted for under the amortized cost basis, except for the pre-funded warrants and warrants which are measured at fair value through profit or loss. The carrying amounts of the Company’s financial assets and financial liabilities provide a reasonable approximation of their fair value, as the impact of discounting is immaterial. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Fair value of financial instruments:</td></tr> </table> The different levels of valuation of financial instruments are defined as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in">Level 1</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Quoted prices (unadjusted) in active markets for identical assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Level 2</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inputs, other than quoted prices included within level 1 that are observable for the asset or liability, either directly (as prices) or indirectly (derived from prices).</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Level 3</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inputs for the asset or liability that are not based on observable market data (unobservable inputs).</td></tr> </table> As described in Note 4, the fair value of the pre-funded warrants is determined using a Level 2 valuation technique, whereas the fair value of the warrants is determined using a Level 3 valuation technique. Changes in the fair value of the pre-funded warrants and warrants are recognized in profit or loss. The theoretical fair value of the granted warrants, calculated using the Black-Scholes model, is based on the following assumptions: share price of $5.56, strike price of $4.8, expected volatility in a rate of <span id="xdx_907_ecustom--DescriptionOfExpectedVolatilityWarrantsGranted_pid_dp_uPure_c20260626__20260626__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--WarrantsMember_z42IHhFFppr9" title="Volatility rate">63.41%, risk-free interest rate of <span id="xdx_90D_ecustom--DescriptionOfRiskFreeInterestRateWarrantsGranted_pid_dp_uPure_c20260626__20260626__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--WarrantsMember_ziPevJMUqgsk" title="Risk-free interest rate">4.12% and expected life of 5 years. SCHEDULE OF FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 1.25in"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20260630__ifrs-full--LevelsOfFairValueHierarchyAxis__ifrs-full--Level2OfFairValueHierarchyMember_zJDcSlnWDjpa" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Level 2</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260630__ifrs-full--LevelsOfFairValueHierarchyAxis__ifrs-full--Level3OfFairValueHierarchyMember_zwgoa6J0ive1" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Level 3</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260630_zBzOkjS3w6b8" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Total</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">NIS in thousands</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold">June 30, 2026:</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_40E_eifrs-full--CurrentWarrantLiability_iI_uNIS_hifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--PrefundedWarrantsMember_zBaB9UirOPn8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; width: 46%; text-align: left">Pre-funded warrants</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">24,708</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">24,708</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eifrs-full--CurrentWarrantLiability_iI_uNIS_hifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--WarrantsMember_znvsodWkfjuf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Ordinary warrants</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">8,490</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">8,490</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eifrs-full--CurrentWarrantLiability_iI_uNIS_zBz02AlnLMkl" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">Financial assets at fair value</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">24,708</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">8,490</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">33,198</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Convenience translation into U.S. dollars (see note 2(b)) <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 1.25in"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260630__ifrs-full--LevelsOfFairValueHierarchyAxis__ifrs-full--Level2OfFairValueHierarchyMember_z85qv24N5I7d" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Level 2</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20260630__ifrs-full--LevelsOfFairValueHierarchyAxis__ifrs-full--Level3OfFairValueHierarchyMember_zuQCFXCGUb4l" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Level 3</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260630_zNrucFiJIB61" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Total</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">NIS in thousands</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold">June 30, 2026:</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40B_eifrs-full--CurrentWarrantLiability_iI_uUSD_hifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--PrefundedWarrantsMember_zA1iQEswoMn" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; width: 46%; text-align: left">Pre-funded warrants</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">8,297</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">8,297</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eifrs-full--CurrentWarrantLiability_iI_uUSD_hifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--WarrantsMember_zhyTFwFeRYq" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Ordinary warrants</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">2,851</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">2,851</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eifrs-full--CurrentWarrantLiability_iI_uUSD_zFNPmM8CrXha" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> Warrants</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">8,297</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">2,851</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">11,148</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS NOTE 5 – FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (cont.) <p id="xdx_898_eifrs-full--DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_zwR3Uw1qrDqc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify">The following table presents the changes in the financial instruments measured within level 3: SCHEDULE OF CHANGES IN THE FINANCIAL INSTRUMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 1.25in"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20260101__20260630_zO3g5hWVk337" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold; text-align: center"></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Convenience translation into U.S. dollars (see note 2(b))</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Six months ended June 30,</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2026</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">NIS in thousands</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">in thousands</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eifrs-full--FairValueOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAssets_iS_pn3n3_uUSD_znmdjf5ZUFd1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold">Balance as of January 1</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_984_eifrs-full--FairValueOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAssets_iS_pn3n3_uUSD_c20260101__20260630_z63YC5qJuig7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Balance as of January 1">-</td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_400_ecustom--InitialRecognitionOfFinancialLiability_pn3n3_uNIS_z9WYEQklAHSg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: left">Initial recognition of financial liability</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right">15,751</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98B_ecustom--InitialRecognitionOfFinancialLiability_pn3n3_uUSD_c20260101__20260630_zHn8avpjk8kl" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Initial recognition of financial liability">5,289</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_ecustom--DeferredLoss_iN_pn3n3_di_uNIS_zALQN7qDJkj1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Deferred day 1 loss</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(7,274</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_ecustom--DeferredLoss_iN_di_uUSD_c20260101__20260630_z4KG2QKT8qW7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Deferred day 1 loss">(2,443</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr id="xdx_402_ecustom--ChangeInFairValueOfWarrants_pn3n3_uNIS_zSC8e4JFp345" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Change in fair value of warrants</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(3</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_ecustom--ChangeInFairValueOfWarrants_uUSD_c20260101__20260630_zjFdXsjOm6E5" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Change in fair value of warrants">(1</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr id="xdx_409_ecustom--ReleaseLoss_iN_pn3n3_di_uNIS_zoJ9YaYHN7Ld" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Release of day 1 loss</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">16</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_ecustom--ReleaseLoss_iN_di_uUSD_c20260101__20260630_zwNgQZgkfDVf" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Release of day 1 loss">5</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eifrs-full--FairValueOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAssets_iE_pn3n3_uNIS_z9WL95qeHme2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt">Balance as of June 30</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">8,490</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eifrs-full--FairValueOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAssets_iE_pn3n3_uUSD_c20260101__20260630_zz0g5udbGCd" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Balance as of June 30">2,850</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

5.56 4.8 0.6341 0.0412 P5Y

SCHEDULE OF FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 1.25in"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20260630__ifrs-full--LevelsOfFairValueHierarchyAxis__ifrs-full--Level2OfFairValueHierarchyMember_zJDcSlnWDjpa" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Level 2</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260630__ifrs-full--LevelsOfFairValueHierarchyAxis__ifrs-full--Level3OfFairValueHierarchyMember_zwgoa6J0ive1" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Level 3</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260630_zBzOkjS3w6b8" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Total</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">NIS in thousands</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold">June 30, 2026:</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_40E_eifrs-full--CurrentWarrantLiability_iI_uNIS_hifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--PrefundedWarrantsMember_zBaB9UirOPn8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; width: 46%; text-align: left">Pre-funded warrants</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">24,708</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">24,708</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eifrs-full--CurrentWarrantLiability_iI_uNIS_hifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--WarrantsMember_znvsodWkfjuf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Ordinary warrants</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">8,490</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">8,490</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eifrs-full--CurrentWarrantLiability_iI_uNIS_zBz02AlnLMkl" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">Financial assets at fair value</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">24,708</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">8,490</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">33,198</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Convenience translation into U.S. dollars (see note 2(b)) <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 1.25in"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260630__ifrs-full--LevelsOfFairValueHierarchyAxis__ifrs-full--Level2OfFairValueHierarchyMember_z85qv24N5I7d" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Level 2</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20260630__ifrs-full--LevelsOfFairValueHierarchyAxis__ifrs-full--Level3OfFairValueHierarchyMember_zuQCFXCGUb4l" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Level 3</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260630_zNrucFiJIB61" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Total</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">NIS in thousands</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold">June 30, 2026:</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40B_eifrs-full--CurrentWarrantLiability_iI_uUSD_hifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--PrefundedWarrantsMember_zA1iQEswoMn" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; width: 46%; text-align: left">Pre-funded warrants</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">8,297</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">8,297</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eifrs-full--CurrentWarrantLiability_iI_uUSD_hifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--WarrantsMember_zhyTFwFeRYq" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Ordinary warrants</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">2,851</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">2,851</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eifrs-full--CurrentWarrantLiability_iI_uUSD_zFNPmM8CrXha" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> Warrants</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">8,297</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">2,851</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">11,148</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

24708000

8490000

24708000

8490000

33198000

8297000

2851000

8297000

2851000

11148000

<p id="xdx_898_eifrs-full--DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_zwR3Uw1qrDqc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify">The following table presents the changes in the financial instruments measured within level 3: SCHEDULE OF CHANGES IN THE FINANCIAL INSTRUMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 1.25in"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20260101__20260630_zO3g5hWVk337" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold; text-align: center"></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Convenience translation into U.S. dollars (see note 2(b))</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Six months ended June 30,</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2026</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">NIS in thousands</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">in thousands</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eifrs-full--FairValueOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAssets_iS_pn3n3_uUSD_znmdjf5ZUFd1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold">Balance as of January 1</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_984_eifrs-full--FairValueOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAssets_iS_pn3n3_uUSD_c20260101__20260630_z63YC5qJuig7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Balance as of January 1">-</td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_400_ecustom--InitialRecognitionOfFinancialLiability_pn3n3_uNIS_z9WYEQklAHSg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: left">Initial recognition of financial liability</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right">15,751</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98B_ecustom--InitialRecognitionOfFinancialLiability_pn3n3_uUSD_c20260101__20260630_zHn8avpjk8kl" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Initial recognition of financial liability">5,289</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_ecustom--DeferredLoss_iN_pn3n3_di_uNIS_zALQN7qDJkj1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Deferred day 1 loss</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(7,274</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_ecustom--DeferredLoss_iN_di_uUSD_c20260101__20260630_z4KG2QKT8qW7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Deferred day 1 loss">(2,443</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr id="xdx_402_ecustom--ChangeInFairValueOfWarrants_pn3n3_uNIS_zSC8e4JFp345" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Change in fair value of warrants</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(3</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_ecustom--ChangeInFairValueOfWarrants_uUSD_c20260101__20260630_zjFdXsjOm6E5" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Change in fair value of warrants">(1</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr id="xdx_409_ecustom--ReleaseLoss_iN_pn3n3_di_uNIS_zoJ9YaYHN7Ld" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Release of day 1 loss</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">16</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_ecustom--ReleaseLoss_iN_di_uUSD_c20260101__20260630_zwNgQZgkfDVf" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Release of day 1 loss">5</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eifrs-full--FairValueOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAssets_iE_pn3n3_uNIS_z9WL95qeHme2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt">Balance as of June 30</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">8,490</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eifrs-full--FairValueOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAssets_iE_pn3n3_uUSD_c20260101__20260630_zz0g5udbGCd" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Balance as of June 30">2,850</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

15751000 5289000 7274000 2443000 -3000 -1000 -16000 -5000

8490000

2850000

NOTE 6 – COMMITMENTS AND CONTINGENT LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">A)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Material agreements</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">1)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Supply Agreement – FC </td></tr></table> On January 21, 2026, the Company signed an addendum to the agreement with Clalit, to supply Pulsenmore FC and to update the commercial understanding between the parties under the Follicle Agreement. According to the addendum the Company and Clalit shall be entitled to market Pulsenmore FC directly to patients. A pilot period of 18 months shall commence upon 30 days from signing the addendum, after which Clalit shall purchase a yearly minimum quantity of the Pulsenmore FC for a period of 5 years for a total consideration of $<span id="xdx_909_eifrs-full--AcquisitiondateFairValueOfTotalConsiderationTransferred_iI_pn6n6_c20260121__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember_z31rRHKrDNAd" title="Total consideration for purchase">9 million. The agreement includes the option to return products by Clalit in accordance with the terms and conditions set forth therein. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">2)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Commercial Engagements with two U.S.-Based Medical Centers</td></tr></table> On January 29, 2026, and on February 4, 2026, the Company entered into a services agreements, in accordance, with the two medical Centers Under those agreements, the medical centers will purchase Pulsenmore ES home ultrasound services. The services agreements are in force for a term of one year and will be renewed automatically for successive one-year periods unless either Party gives at least 30 days’ written notice of non-renewal before the end of the then-current term. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">3)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Ouma Health</td></tr></table> On June 17, 2026, the Company entered into a strategic partnership with Ouma Health to expand access to remote prenatal care across the United States. The collaboration is intended to support care delivery for underserved patient populations, including those living in maternity deserts and underserved communities, and to generate insights and experience that may support future expansion opportunities with healthcare systems, maternity care providers and payer organizations. NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Clalit shall purchase a yearly minimum quantity of the Pulsenmore FC for a period of 5 years

9000000

NOTE 7 – SUBSEQUENT EVENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">A)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Regulatory Sandbox and SmartScan AI Programs</td></tr> </table> On July 2, 2026, the Company was selected to participate in Israel’s Healthcare AI Regulatory Sandbox Program, established by the Israel Innovation Authority (hereinafter – the “IIA”) and the Ministry of Health. As part of the program, the Company expects to lead a project valued at NIS <span id="xdx_909_eifrs-full--GovernmentGrants_iI_pn6n6_uNIS_c20260702__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember__ifrs-full--TypesOfContractsAxis__custom--HealthcareAIRegulatorySandboxProgramMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IsraelInnovationAuthorityMember_z9n8acuBmDri">3 million (approximately $<span id="xdx_909_eifrs-full--GovernmentGrants_iI_pn6n6_uUSD_c20260702__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember__ifrs-full--TypesOfContractsAxis__custom--HealthcareAIRegulatorySandboxProgramMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IsraelInnovationAuthorityMember_zi7gMlWemmH5" title="Project value">1 million). The grant approved amounted to NIS <span id="xdx_90C_eifrs-full--ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities_pn5n6_uNIS_c20260702__20260702__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember__ifrs-full--TypesOfContractsAxis__custom--HealthcareAIRegulatorySandboxProgramMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IsraelInnovationAuthorityMember_zSXoNunMNluh" title="Grant value">1.2 million (approximately $<span id="xdx_908_eifrs-full--ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities_pn5n6_uUSD_c20260702__20260702__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember__ifrs-full--TypesOfContractsAxis__custom--HealthcareAIRegulatorySandboxProgramMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IsraelInnovationAuthorityMember_zMgAelpOHLe2" title="Grant value">0.4 million). On August 12, 2026 the IIA approved an additional amount of NIS <span id="xdx_900_eifrs-full--ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities_pn5n6_uNIS_c20260812__20260812__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IsraelInnovationAuthorityMember__ifrs-full--TypesOfContractsAxis__custom--SmartScanAIProgramMember_zW98maQLCw73" title="Additional amount">3.8 million (approximately $<span id="xdx_90B_eifrs-full--ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities_pn4n6_uUSD_c20260812__20260812__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember__ifrs-full--TypesOfContractsAxis__custom--SmartScanAIProgramMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IsraelInnovationAuthorityMember_zmku1Gj2Cax" title="Grant approved amount">1.27 million) as a grant to the Company for SmartScan AI Program. As to date of this report, the Company has not received any grants under these programs and has not yet incurred any related costs.

3000000

1000000

1200000

400000

3800000

1270000

Basic loss per share does not include the above-mentioned 1,562,500 pre-funded warrants since they are accounted for as a liability. In addition, the impact of the pre-funded warrants has not taken in the diluted weighted average number of ordinary shares calculation as their effect would have been anti-dilutive. Less than NIS 1 thousand